Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer

Authors:

Abstract
The anti-HER2 monoclonal antibody trastuzumab and new derivative formulations are the standard treatment for HER2-positive breast cancer. However, after 1 to 5 years of treatment, some patients acquire resistance to therapy, leading to relapse. The microRNA-449 family members were downregulated in HER2-positive breast cancer cell lines and low levels were associated with patients’ worse prognosis. Moreover, trastuzumab-resistant HER2-positive breast cancer cell lines showed lower microRNAs-449 and higher Fatty Acid Synthase (FASN) expression, compared to sensitive cell lines. The direct regulation of FASN by microRNA-449a and microRNA-449b-5p was demonstrated. Moreover, microRNAs-449 overexpression and FASN inhibition decreased cell proliferation and sensitized cells to trastuzumab treatment by inhibiting the PI3K/AKT signaling pathway. Together, these results suggest the microRNAs-449/FASN axis as a potential therapeutic target in combination with anti-HER2 agents to overcome trastuzumab resistance and to improve treatment response in HER2-positive breast cancer patients.
Funding Information
  • Asociación Española Contra el Cáncer (PRDVA19016LAME)
  • Conselleria d’Educació, Investigació, Cultura i Esport, Generalitat Valenciana (ACIF/2019/119)
  • European Union-Next Generation EU (Margarita Salas postdoctoral grant)
  • Spanish Government and cofinanced by FEDER Funds (PI21/00002, PI21/00142, PI21/01351)
  • Spanish Government CIBERONC (CB16/12/00241, CB16/12/00481)
  • Sociedad Española de Oncología Médica (Río Hortega-SEOM)

This publication has 41 references indexed in Scilit: